Newave Pharmaceutical Inc.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Newave Pharmaceutical Inc..The latest application filed is for "condensed heterocyclic derivates as bcl-2 inhibitors for the treatment of neoplastic diseases".
- Newave Pharmaceutical Inc. - Pleasanton CA US
| Patent | Date |
|---|---|
| Condensed Heterocyclic Derivates As Bcl-2 Inhibitors For The Treatment Of Neoplastic Diseases App 20220220126 - Chen; Yi ; et al. | 2022-07-14 |
| BCL-2 inhibitors Grant 11,365,206 - Chen , et al. June 21, 2 | 2022-06-21 |
| Inhibitor Of Btk And Mutants Thereof App 20220135569 - Chen; Yi | 2022-05-05 |
| Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases Grant 11,279,711 - Chen , et al. March 22, 2 | 2022-03-22 |
| 1h-pyrrolo[2,3-b]pyridine Derivatives And Related Compounds As Bcl-2 Inhibitors For The Treatment Of Neoplastic And Autoimmune Diseases App 20220073513 - Chen; Yi | 2022-03-10 |
| Bcl-2 Inhibitors App 20210332065 - Chen; Yi | 2021-10-28 |
| Bcl-2 Inhibitors App 20210315904 - Chen; Yi | 2021-10-14 |
| Bcl-2 Inhibitors App 20210171523 - Chen; Yi ; et al. | 2021-06-10 |
| 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one Compounds As Inhibitors Of Wee-1 Kinase App 20210061807 - Chen; Yi | 2021-03-04 |
| Inhibitors Of Btk And Mutants Thereof App 20200377478 - Chen; Yi | 2020-12-03 |
| Covalent Inhibitors Of Cdk-7 App 20200297724 - Chen; Yi ; et al. | 2020-09-24 |
| Novel Therapeutic Agents For The Treatment Of Hbv Infection App 20200223841 - Chen; Yi ; et al. | 2020-07-16 |
| Bcl-2 Inhibitors App 20200197406 - Chen; Yi ; et al. | 2020-06-25 |
| Condensed Heterocyclic Derivates As Bcl-2 Inhibitors For The Treatment Of Neoplastic Diseases App 20200190109 - Chen; Yi ; et al. | 2020-06-18 |
| Bcl-2 Inhibitors App 20200071329 - Chen; Yi ; et al. | 2020-03-05 |
| Therapeutic agents for the treatment of HBV infection Grant 10,501,456 - Chen , et al. Dec | 2019-12-10 |
| Covalent inhibitors of CDK-7 Grant 10,456,397 - Chen , et al. Oc | 2019-10-29 |
| BCL-2 inhibitors Grant 10,377,755 - Chen , et al. A | 2019-08-13 |
| Novel Therapeutic Agents For The Treatment Of Hbv Infection App 20190169182 - Chen; Yi ; et al. | 2019-06-06 |
| Covalent Inhibitors Of Cdk-7 App 20190151316 - Chen; Yi ; et al. | 2019-05-23 |
| Dual-warhead covalent inhibitors of FGFR-4 Grant 10,253,029 - Chen , et al. | 2019-04-09 |
| Therapeutic agents for the treatment of HBV infection Grant 10,239,872 - Chen , et al. | 2019-03-26 |
| Bcl-2 Inhibitors App 20190040062 - Chen; Yi ; et al. | 2019-02-07 |
| Covalent inhibitors of CDK-7 Grant 10,195,200 - Chen , et al. Fe | 2019-02-05 |
| Novel Therapeutic Agents For The Treatment Of Hbv Infection App 20180170925 - Chen; Yi ; et al. | 2018-06-21 |
| Covalent Inhibitors Of Cdk-7 App 20180008604 - Chen; Yi ; et al. | 2018-01-11 |
| Dual-warhead Covalent Inhibitors Of Fgfr-4 App 20170305918 - Chen; Yi ; et al. | 2017-10-26 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 